Search Results
CAR-T Immunotherapy Showing Positive Results
This week, positive data from a Kite Pharma CAR-T immunotherapy clinical trial was released showing that more than one-third of refractory aggressive non-Hodgkin lymphoma (NHL) patients in the study showed no signs of the disease after six months.
Since 2015, The Leukemia & Lymphoma Society has been funding this study through its collaboration with Kite Pharma, a biotechnology company focused on immunotherapy.
FAQs: Proposed federal spending cuts and blood cancer research and care
The Leukemia & Lymphoma Society (LLS) has heard great concerns from patients, caregivers, volunteers, healthcare professionals, researchers, community organizations and others who are fearful and confused by NIH spending cuts and other policies being proposed and implemented in Washington.
Another First: FDA Approves Car T-Immunotherapy for Treatment of Aggressive Form of Indolent Non-Hodgkin Lymphoma
The U.S. Food and Drug Administration (FDA) today approved the CAR T-cell treatment axicabtagene ciloleucel (Yescarta®) for patients with follicular lymphoma (FL) that has returned or worsened despite earlier treatment. FL is the most common slow-growing non-Hodgkin’s lymphoma and while the disease can generally be managed, reoccurrence is common.
Shop Online and In-Store at Walgreens to Support LLS
The Leukemia & Lymphoma Society (LLS) and Walgreens are in your corner.
Since 2019, Walgreens has helped to raise more than $30 million for LLS and Susan G. Komen, all with a clear goal in mind: to advance research for tough-to-treat cancers and increase equitable access to care.
Balancing fiscal responsibility with saving and improving lives
Table of contents:
Defining and Redefining a Blood Cancer Diagnosis
Science historian June Goodfield wrote, “Cancer begins and ends with people.”
This Blood Cancer Awareness Month, it’s important to know that The Leukemia & Lymphoma Society (LLS) is on a mission to cure blood cancers and improve quality of life for the nearly 1.7 million people in the U.S. living with or in remission from blood cancer.
LLS is all about people—an organization full of people who are united in the urgent effort to help every person impacted by blood cancer.
Blood Cancer Survivors Find Special Meaning and Connection as Employee Champions of LLS Light the Night Events
The Leukemia & Lymphoma Society (LLS) is proud of our continuing partnership with Gilead and Kite Oncology as the National Presenting Sponsor of Celebration and Community at Light The Night events across the U.S. helping bring people together and raise critical funds to support patients and their families.
Understanding Myeloma: A Quick Guide
Myeloma is a rare blood cancer
We Dare to Dream so Their Dreams Come True
Did you know that blood cancer is the most common cancer diagnosis for children, accounting for 40% of pediatric cancer cases? In fact, nearly 55,000 children and adolescents in the United States currently have blood cancer or are in remission from blood cancer.
Why Monthly Giving Matters
Giving regularly over time = giving patients and survivors the chance for more time.
Monthly giving really deserves more credit—credit as a predictable, impactful funding force for our lifesaving and life-changing work. For The Leukemia & Lymphoma Society (LLS), the reliability of a regular gift helps to sustain cutting-edge research and to provide the free resources and support blood cancer patients and survivors need to live longer, better lives.
It’s about ongoing generosity. It’s about creating a lasting impact.
And...
Ushering In a New Era of Pediatric Blood Cancer Treatment and Care
We caught up with Gwen Nichols, MD, Chief Medical Officer at The Leukemia & Lymphoma Society (LLS), to share the progress we’re making to bring cures and better care to children with blood cancer through The LLS Children’s Initiative.
Tell us about The LLS Children’s Initiative and why it’s so important to you and LLS.
People with CLL are living longer than ever before, and cures are on the horizon
People with the most common type of blood cancer, chronic lymphocytic leukemia (CLL), are living longer than ever before without their disease progressing. While cures for CLL patients are still rare, survival rates have improved steadily over the last 50 years, with nearly 90 percent of people diagnosed with CLL today surviving at least five years, and most for many years longer.
The Immune System and Blood Cancer: 4 Things You Need to Know
Immunotherapy uses the power of the immune system to treat blood cancer. Today it is a standard treatment that has a profound effect in some blood cancer patients, but it still falls short in others.
The Leukemia & Lymphoma Society (LLS) has been a champion of this type of cancer treatment for decades, supporting some of the earliest and most game-changing immune-based treatments for blood cancer. The advances have been astonishing, but there is so much further to go.
The Leukemia & Lymphoma Society's New Chief Scientific Officer Excited about What's Next in Blood Cancer Research
Lore Gruenbaum, Ph.D., was promoted to The Leukemia & Lymphoma Society’s (LLS) Chief Scientific Officer (CSO) following the retirement of longtime CSO Lee Greenberger, Ph.D. on December 31. We talked with Dr. Gruenbaum about her new role and what’s on the horizon for blood cancer research in 2025.
“It’s a privilege to lead a group of dedicated LLS scientists to seek out and fund innovative science for every type of blood cancer,” says Dr. Gruenbaum.
Because You Volunteer, Your Impact Creates a Ripple Effect
When you commit time and talent to a nonprofit’s mission – no matter how you choose to get involved – you become a volunteer, and the impact of your efforts runs far deeper than the specific project or task you work on. For example, volunteers don’t always realize that the hours they spent stocking shelves meant hundreds of families would have food for two weeks. Or that the time spent fundraising not only raised critical mission dollars but also added value upward of $1,250 to the organization’s bottom line.
FDA Approves First CAR T-Immunotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia
The U.S. Food and Drug Administration (FDA) recently announced approval of brexucabtagene autoleucel (Tecartus®) as the first and only CAR T-cell treatment for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). Roughly half of all ALL cases occur in adults, and unlike pediatric ALL, adults have historically had a poor prognosis. This approval, which follows an FDA Breakthrough Therapy Designation and priority review, is a meaningful advance for these patients.
Helping Survivors Lead Longer Better Lives
Late last year I had the privilege of attending a special screening of the documentary American Symphony. The film chronicles the experiences of writer Suleika Jaouad and her husband musician Jon Batiste after learning that her acute myeloid leukemia (AML) had returned after years of remission. The movie shows how the couple navigates uncertainty, treatment, and their new normal afterwards.
Blood Cancer Research Poised for Another ‘Banner Year’ in 2024
More than 25,000 medical professionals from across the world came together in December to discuss the latest blood cancer developments during the annual meeting of the American Society of Hematology (ASH). This annual event gives us the opportunity to think about what advances are on the horizon as LLS works to strengthen cures, care and quality of life for people with blood cancer and their families.
Exercise for blood cancer patients
Table of contents:
Improving Blood Cancer Survival Takes More than New Drug Discovery
In my years as a practicing hematologist-oncologist and now as chief medical officer of The Leukemia & Lymphoma Society (LLS), I’ve met many blood cancer patients who worry about how they’ll afford their treatment on top of day-to-day expenses like rent and groceries. LLS offers financial assistance for qualifying blood cancer patients and families
What Is Blood Cancer?
Reviewed by Gwen Nichols, MD, EVP and Chief Medical Officer at The Leukemia & Lymphoma Society
